Sunday, May 24, 2015

Daniel Hoffman

Two updates on pharma news

Thursday, August 29, 2013, 9:19 AM
Earlier this month we discussed how a major device manufacturer, Medtronic, blazed a trail for pharma by purchasing Cardiocom, a company that provides disease management and monitoring data for heart patients. Medtronic is well aware of the challenges facing device makers and the company decided to... Read more

Pharma's Denial and Rationalization Working Overtime

Monday, August 12, 2013, 11:42 AM
Evidence emerges almost every day that pharma's managers recognize the existence of serious problems threatening their industry, while at the same time most of them refuse to acknowledge the causes of this situation. Last week, for example, a provider of online marketing research released the results... Read more

A lesson or two from GSK's Chinagate

Monday, July 29, 2013, 6:00 AM
GlaxoSmithKline's (GSK's) Chinagate scandal of the past few weeks provides some belated insight on the China fantasy that pharma has been peddling to investors for much of the last decade. The basic pretense that pharma could somehow offset its wave of patent expirations, its dearth of compelling... Read more

Problems developing effective Alzheimer's therapies

Friday, July 19, 2013, 6:05 AM
Last week Eli Lilly announced that later this year it would start another late-stage (Phase 3) study of its monoclonal antibody, solanezumab, to test whether it can slow the advance of Alzheimer's disease. A pair of solanezumab Phase 3 trials last year failed to show efficacy in patients with mild-to-moderate... Read more

Which side is Pharma on?

Wednesday, July 10, 2013, 6:05 AM
Even as some health care trends slowly work their way to the surface, the mass media remains five years behind reality and has yet to recognize them. Yet the reactions of the world's nations to these trends will determine the nature of global health care in 2020 and beyond. The positions pharma takes... Read more

Nice bonds for conservative investors

Thursday, June 27, 2013, 10:12 AM
A monthly review of Big Cap pharma stocks by Sanford Bernstein, a large fee-analyst company, offers some insights in what it says and what it doesn't say. As with other equity analysts, Bernstein draws a wide distinction between a company's/sector's fundamentals and its value as a stock. Based on... Read more

The reactionary myth that's letting finance managers ruin pharma companies

Wednesday, June 19, 2013, 6:00 AM
Pharma's finance managers have come in for some heavy hits in this space during the past two years. They deserve every swat and then some. CFOs and their henchmen have destroyed Big Pharmas foundation as research-driven, growth companies and have driven off some of its most experienced, capable people... Read more

Pharma as a fading power hitter

Wednesday, June 12, 2013, 6:00 AM
Approximately half the drugs now in clinical development involve an approach known as targeted therapy. Last week's posting discussed some of the problems associated with that strategy. These include increasing the risks of drug development, price gouging, fostering a blind-leading-the-blind phenomenon... Read more

Pharma needs an R&D strategy

Thursday, June 6, 2013, 10:08 AM
Recently a knowledgeable pharma veteran lamented the fact that the industry has not widely adopted what he considers a particularly useful approach to drug development. One company "had it right," he wrote, "when their research model was to study particular pathways and find drugs to affect various... Read more

Organize health care as if it was war

Wednesday, May 29, 2013, 6:00 AM
Does the private control of drug development and health care in general bestow better health and prosperity on Americans? For people in the C-suites, their bluestocking shareholders and some others, it undoubtedly does. For most Americans, it doesn't appear to work so well. Earlier this year the... Read more
About this blog

Check Up covers regional health news and a wide array of healthcare topics from pharmaceutical happenings to patient safety. Read about some of our bloggers here.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on
letter icon Newsletter